Announcement
Surgical Innovations : Launch of the Green Surgery Challenge
RNS Number : 3853O
Surgical Innovations Group PLC
09 February 2021
Surgical Innovations Group plc
("Surgical Innovations", "SI" or the "Company")
Launch of the Green Surgery Challenge
Event sponsor to promote the use of sustainable products in surgery
Surgical Innovations Group plc (AIM: SUN), the designer, manufacturer and distributor of innovative medical technology for minimally invasive surgery ("MIS"), announces that Elemental Healthcare Limited, a wholly owned SI subsidiary, was a key sponsor at the launch of the Green Surgery Challenge 2021*, which took place last week.
This competition , initiated by Elemental Healthcare and developed by the Centre for Sustainable Healthcare ("CSH"), allows UK operating theatres to present innovative ideas to reduce their Carbon Footprint. The national competition has been organised by the CSH, Royal College of Surgeons England, Royal College of Surgeons of Scotland and NIHR Surgical Med Tech Co-op and is endorsed by a number of significant charities and official bodies.
The Green Surgery Challenge 2021 is an opportunity for the UK's surgical community to recognise the value of sustainable healthcare for surgical conditions, share and promote ways of practicing that are less harmful to the environment and the planet and build social sustainability, transforming surgery for the future. The launch event attracted over 400 delegates.
The recording can be accessed here: https://youtu.be/Nb2EimC2-0c
As announced in November 2020, SI has an ongoing collaboration with the CSH, enabling the Company to validate the environmental messaging for SI's products and demonstrate the quantifiable benefits in cost and environmental savings from a 'greener' operating room, with particular focus on reducing plastic waste in surgery in the UK and globally.
Adam Power, SI Group Development Director, commented: "We are pleased to be part of the Green Surgery Challenge launch, bringing sustainability to the forefront of hospital agendas. We are one of the only significant players in the space with our Resposable TM product portfolio and are passionate to lead and support innovative ideas to reduce public sector waste and emissions, much of which comes from NHS surgical procedures."
*More information on the Green Surgery Challenge 2021 can be found here - Green Surgery Challenge | Centre for Sustainable Healthcare
For further information please contact:
|
Surgical Innovations Group plc |
|
|
David Marsh, CEO |
Tel: 0113 230 7597 |
|
Charmaine Day, Co Sec & GFC |
|
|
|
|
|
N+1 Singer (Nominated Adviser & Broker) |
Tel: 020 7496 3000 |
|
Aubrey Powell / Rachel Hayes/ Iqra Amin |
|
|
|
|
|
Walbrook PR (Financial PR & Investor Relations) |
Tel: 020 7933 8780 or [email protected] |
|
Paul McManus / Lianne Cawthorne |
Mob: 07980 541 893 / 07584 391 303 |
About Surgical Innovations Group plc
The Group specialises in the design, manufacture, sale and distribution of innovative, high quality medical products, primarily for use in minimally invasive surgery. Our product and business development is guided and supported by a key group of nationally and internationally renowned surgeons across the spectrum of minimally invasive surgical activity.
We design and manufacture and source our branded port access systems, surgical instruments and retraction devices which are sold directly in the UK home market through our subsidiary, Elemental Healthcare, and exported widely through a global network of trusted distribution partners. Many of our products in this field are based on a "resposable" concept, in which the products are part re-usable, part disposable, offering a high quality and environmentally responsible solution at a cost that is competitive against fully disposable alternatives.
Elemental also has exclusive UK distribution for a select group of specialist products employed in laparoscopy, bariatric and metabolic surgery, hernia repair and breast reconstruction.
In addition, we design and develop medical devices for carefully selected OEM partners, and have also collaborated with a major UK industrial partner to provide precision engineering solutions to complex problems outside the medical arena.
We aim for our brands to be recognised and respected by healthcare professionals in all major geographical markets in which we operate and provide by development, partnership or acquisition a broad portfolio of cost effective, procedure specific surgical instruments and implantable devices that offer reliable solutions to genuine clinical needs in the operating theatre environment.
The Group currently employs approximately 100 people across two sites in the UK. Product design, engineering and manufacturing are carried out at the SI site in Yorkshire. Commercial activities including marketing, UK distribution and international sales and marketing are based at Elemental Healthcare in Berkshire.
Further information
Further details of the Group's businesses are available on the following websites:
To receive regular updates by email, please contact [email protected] .
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
NRAMZGGZMRNGMZZ
;